GEN Exclusives

More »

GEN News Highlights

More »
Jan 15, 2008

Investigators Uncover the Workings of Epstein-Barr Virus in Cancer

  • Researchers from GSF–National Research Centre for Environment and Health say that they have identified the way that the Epstein-Barr virus manipulates tumor necrosis factor-receptor 1-associated death domain protein (TRADD) to establish itself in the host.

    Epstein-Barr virus alters the way B lymphocytes behave, transforming them into cancerous cells that survive and divide more than they should, the team explains. They studied the way that TRADD interacts with LMP1, a protein produced by the virus that is essential for cell transformation. The scientists genetically altered cells so that they wouldn’t produce any TRADD and found that these cells didn’t respond to the transformation signals sent by the LMP1 protein.

    The research group also studied the shape of the viral protein LMP1 and say that a region of it binds to TRADD in a unique way. When TRADD is bound to LMP1, it is unable to interact with the molecules that it normally would and hence it cannot cause cell death, they explain.

    The investigators also took this TRADD binding site and used it to replace the TRADD binding site on the host cellular protein that mediates cell death. This was enough to convert the cellular protein into a nonapoptotic receptor and thus to stop TRADD from inducing apoptosis, they report.

    The study is published on January 15 in PLoS Biology.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?